BMY
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company historical holders
total: 20
Hillman Value Fund Bristol-Myers Squibb Company transactions over time
- Total transactions:
- 10
- New positions:
- 2
- Sold out:
- 1
- Added:
- 3
- Reduced:
- 4
- Held since:
- 2024 Q2
- Held for:
- 8 quarters
- Latest activity:
- 2025 Q4
Mark A. Hillman has been an institutional investor in Bristol-Myers Squibb Company (BMY) since 2020 Q1. According to 2026 Q1 report, Mark A. Hillman holds 46,400 shares with a market value of roughly $2.81M representing 3.39% of their equity portfolio. The fund/company first acquired BMY in 2020 Q1, initially purchasing 46,000 shares. Mark A. Hillman later completely sold out the position and reinvested in BMY again in 2024 Q2. Since the initial investment, Hillman Value Fund has made 9 more transactions in this position.
Does Mark A. Hillman still hold BMY?
Yes, Mark A. Hillman continues to hold Bristol-Myers Squibb Company (BMY). According to their 2026 Q1 report, they maintain a position of 46,400 shares valued at approximately $2.81M, representing 3.39% of their equity portfolio.
When did Mark A. Hillman first invest in BMY?
Mark A. Hillman first invested in Bristol-Myers Squibb Company (BMY) in 2020 Q1 at the reported quarter-end price of $55.74 per share, acquiring 46,000 shares in their initial purchase.
What is Mark A. Hillman's average cost basis for BMY?
Based on historical transaction data, Mark A. Hillman's estimated cost basis for Bristol-Myers Squibb Company (BMY) is approximately $41.70 per share. This represents their average reported price* across all buy transactions.
Has Mark A. Hillman reinvested in BMY after selling?
Yes, Mark A. Hillman has shown renewed interest in Bristol-Myers Squibb Company (BMY). After completely selling their position, they reinitiated an investment in 2024 Q2, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $41.70
- Weighted AVG sell price:
- $57.79
BMY transactions history by Hillman Value Fund
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q4
|
2.67%
|
46,400
|
$53.94
|
$2,502,816
|
-25.28% (-15,700)
|
-0.81%
|
|
2025 Q3
|
2.67%
|
62,100
|
$45.10
|
$2,800,710
|
-4.90% (-3,200)
|
-0.12%
|
|
2025 Q2
|
2.55%
|
65,300
|
$46.29
|
$3,022,737
|
+9.38% (+5,600)
|
+0.22%
|
|
2025 Q1
|
2.56%
|
59,700
|
$60.99
|
$3,641,103
|
-45.08% (-49,000)
|
-1.42%
|
|
2024 Q4
|
2.91%
|
108,700
|
$56.56
|
$6,148,072
|
-29.42% (-45,300)
|
-1.12%
|
|
2024 Q2
|
2.82%
|
154,000
|
$41.53
|
$6,395,620
|
new
|
+2.82%
|
|
2022 Q2
|
0.00%
|
0
|
$73.03
|
|
-100% (-93,000)
|
-2.76%
|
|
2021 Q3
|
2.55%
|
93,000
|
$59.17
|
$5,502,810
|
+19.23% (+15,000)
|
+0.41%
|
|
2021 Q1
|
2.85%
|
78,000
|
$63.13
|
$4,924,140
|
+69.57% (+32,000)
|
+1.17%
|
|
2020 Q1
|
3.58%
|
$55.74
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.